Abstract:
The EUA 2018 guidelines recommend that patients with high-risk NMIBC receive either intravesical BCG or radical cystectomy. BCG therapy is difficult to tolerate by patients and some patients are not suitable for cystectomy. The hyperthermic intravesical chemotherapy (HIVEC) can be an alternative method for this category of patients, and a large number of studies currently underway confirms this. HIVEC is presented in EAU Guidelines 2018 for non-muscle-invasive bladder cancer. We present the early results of our series in patients treated with COMBAT BRS-HIVEC recirculation system. Objective. To study the efficacy and safety of adjuvant treatment of patients with non-muscleinvasive bladder cancer by using the method of hyperthermic intravesical chemotherapy of the bladder in adjuvant mode.
